Skip to main content
OpenTrials
Completed

NCT Number: NCT05781243

Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation

Background: Some evidence suggests that fluid resuscitation with lactated Ringer's solution (LR) may have an anti-inflammatory effect on acute pancreatitis (AP) when compared to normal saline (NS), and may be associated with a decrease in severity, but existing single center randomized controlled trials showed conflicting results. The WATERLAND trial aims to investigate the efficacy and safety of fluid resuscitation using LR compared to NS in patients with AP.

Methods: The WATERLAND trial is an international multicenter, open-label, parallel-group, randomized, controlled, superiority trial. Patients will be randomly assigned in a 1:1 ratio to receive LR versus NS-based fluid resuscitation for at least 48 hours. The primary outcome will be moderately severe or severe AP, according to the revision of the Atlanta classification. The secondary objectives of the WATERLAND trial are to determine the effect of LR versus NS fluid resuscitation on several efficacy and safety outcomes in patients with AP.

A total sample of 720 patients, 360 in the LR group and 360 in the NS group, will achieve 90% power to detect a difference between the group proportions of 10%, assuming that the frequency of moderately severe or severe AP in the LR group will be 17%. A loss to follow-up of 10% of patients is expected, so the total sample size will be 396 patients in each treatment arm (792 patients overall). The test statistic used is the two-sided Z test with pooled variance set at a 0.05 significance level.

Discussion: The WATERLAND study aims to improve the early management of AP. Fluid resuscitation is an inexpensive treatment available in any hospital center worldwide. If a better evolution of pancreatitis is demonstrated in one of the treatment arms, it would have important repercussions in the management of this frequent disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Dr. Balmis General University Hospital

Alicante, 03010, Spain

About this study

The entire protocol is published in open-access format, including the Statistical Analysis plan, in the journal Trials: https://doi.org/10.1186/s13063-024-08539-2

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient is 18 years or older
  • Diagnosis of acute pancreatitis according to the revision of the Atlanta classification (Banks et al, Gut 2013), which requires at least two of the following three criteria: A) typical abdominal pain, B) increase in serum amylase or lipase levels higher than three times the upper limit of normality, and C) signs of acute pancreatitis in imaging
  • Signature of informed consent

Exclusion criteria

  • New York Heart Association class II heart failure (slight limitation of physical activity; fatigue, palpitations, or dyspnea with ordinal physical activity) or worse, or ejection fraction <50% in the last echocardiography
  • Decompensated cirrhosis (Child's class B or C)
  • Hyper or hyponatremia (<135 or >145 mEq/L)
  • Hyperkalemia (>5 mEq/L)
  • Hypercalcemia (albumin or protein-corrected calcium >10.5 mg/dL or 2.62 mmol/L)
  • Criteria for moderately severe or severe acute pancreatitis (revision of the Atlanta classification, Banks et al, Gut 2013) at recruitment: any of the following: A) presence of creatinine ≥1.9 mg/dL or ≥170 mmol/l, B) PaO2/FiO2≤300, C) systolic blood pressure <90 mmHg despite initial fluid resuscitation, D) presence of local complications (acute peripancreatic fluid collections, acute necrotic collection, pseudocyst, walled-off necrosis, gastric outlet dysfunction, splenic or portal vein thrombosis, or colonic necrosis), E) exacerbation of previous comorbidity such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis
  • Signs of volume overload or heart failure at recruitment (peripheral edema, pulmonary rales, or increased jugular ingurgitation at 45º)
  • Time from pain onset to arrival to emergency room >24 h
  • Time from confirmation of pancreatitis to randomization >8 h
  • Chronic pancreatitis defined by a Wirsung duct ≥4mm and/or pancreatic calcifications
  • More than 1 previous episode of acute pancreatitis (only 2 episodes of acute pancreatitis are allowed, one of them the present episode)

Treatment and study plan

Lactated Ringer Solution

Drug

Patients in the LR (Lactated Ringer solution) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.

normal saline

Drug

Patients in the NS (Normal Saline) treatment arm will receive fluid therapy based on lactated Ringer's solution for a minimum of 48 hours.

Primary outcomes

  1. Number of Participants with moderately severe or severe acute pancreatitis

    Time frame: From date of randomization until 30 days after randomization

    Presence of local complications, exacerbation of previous comorbidity or organ failure, according to the definitions of these complications provided by the revised Atlanta Classification (https://doi.org/10.1136/gutjnl-2012-302779)

Secondary outcomes

  1. Number of participants with local complications

    Time frame: From date of randomization until 30 days after randomization

    Presence of acute peripancreatic fluid collections, acute necrotic collection, pseudocyst, walled-off necrosis, gastric outlet dysfunction, splenic or portal vein thrombosis, and colonic necrosis according to the revised Atlanta Classification (https://doi.org/10.1136/gutjnl-2012-302779).

  2. Number of participants with necrotizing pancreatitis

    Time frame: From date of randomization until 30 days after randomization

    Presence of acute necrotic collections according to the revised Atlanta Classification (https://doi.org/10.1136/gutjnl-2012-302779).

  3. Number of participants with infection of pancreatic collections or necrosis

    Time frame: From date of randomization until 30 days after randomization

    Extraluminal gas in the pancreatic and/or peripancreatic tissues on CT scan or when a sample from the collection/necrosis contains pus or is positive for bacteria and/or fungi on Gram stain or culture.

  4. Number of participants with systemic inflammatory response syndrome

    Time frame: At 24 and 48 hours

    At least 2 criteria: A) pulse >90 beats/min, B) respirations >20/min or arterial blood PaCO2 <32 mm Hg, C) temperature <36°C or >38°C, D) white blood cell count <4,000 cells/mm3 or >12,000 cells/mm3 or >10% bands

  5. Number of systemic inflammatory response syndrome criteria

    Time frame: At 24 and 48 hours

    The criteria are: A) pulse >90 beats/min, B) respirations >20/min or arterial blood PaCO2 <32 mm Hg, C) temperature <36°C or >38°C, D) white blood cell count <4,000 cells/mm3 or >12,000 cells/mm3 or >10% bands

  6. PAN-PROMISE symptom scale

    Time frame: At 24 and 48 hours (final value and change from baseline)

    PAN-PROMISE scale: a 7-symptom scale patient-reported outcome (range, 0 to 10 for each symptom; overall range, 0 to 70, with higher scores indicating higher symptom intensity). Details: https://doi.org/10.1136/gutjnl-2020-320729

  7. Time to oral refeeding

    Time frame: From date of randomization until 30 days after randomization

    Days from baseline to oral refeeding

  8. Number of participants with invasive treatment

    Time frame: From date of randomization until 30 days after randomization

    Any of the following: thoracocentesis due to pancreatitis-induced pleural effusion, percutaneous and/or endoscopic drainage of pancreatic or peripancreatic fluid collections or necrosis, endoscopic or surgical necrosectomy, endoscopic retrograde cholangiopancreatography due to A) ruptured common bile duct, B) jaundice caused by compression of the common bile duct, C) main pancreatic duct leakage

  9. Number of participants with nutritional support

    Time frame: From date of randomization until 30 days after randomization

    Use of enteral (nasogastric or nasojejunal) or parenteral feeding

  10. Number of participants with intensive care unit admission

    Time frame: From date of randomization until 30 days after randomization

    Admission in the intensive care unit

  11. Number of participants with exacerbation of coexisting condition

    Time frame: From date of randomization until 30 days after randomization

    Exacerbation of pre-existing co-morbidity. The definition provided by the Revised Atlanta Classification is " Exacerbation of pre-existing co-morbidity, such as coronary artery disease or chronic lung disease, precipitated by the acute pancreatitis is defined as a systemic complication. In this document, we distinguish between persistent organ failure (the defining feature of severe acute pancreatitis) and other systemic complications, which are an exacerbation of pre-existing co-morbid disease." (revised Atlanta classification: https://doi.org/10.1136/gutjnl-2012-302779) For the WATERLAND trial we define exacerbation of pre-existing co-morbidity as

  12. Number of participants with any organ failure

    Time frame: From date of randomization until 30 days after randomization

    Definition according to the revised Atlanta classification (https://doi.org/10.1136/gutjnl-2012-302779): organ failure is defined by the presence of any of the following criteria: A) kidney failure as a creatinine ≥1.9 mg/dL or >170 micromol/L, B) cardiovascular failure as a systolic blood pressure <90 mmHg despite fluid resuscitation, and C) respiratory failure as a PaO2/FIO2≤300

  13. Number of participants with persistent organ failure

    Time frame: From date of randomization until 30 days after randomization

    Organ failure lasting more than 48h (revised Atlanta classification: https://doi.org/10.1136/gutjnl-2012-302779)

  14. Number of participants with shock

    Time frame: From date of randomization until 30 days after randomization

    Systolic blood pressure <90 mmHg despite fluid resuscitation (revised Atlanta classification: https://doi.org/10.1136/gutjnl-2012-302779)

  15. Number of participants with respiratory failure

    Time frame: From date of randomization until 30 days after randomization

    PaO2/FIO2≤300 (revised Atlanta classification: https://doi.org/10.1136/gutjnl-2012-302779)

  16. Number of participants with kidney failure

    Time frame: From date of randomization until 30 days after randomization

    Creatinine ≥1.9 mg/dL or >170 micromol/L (revised Atlanta classification: https://doi.org/10.1136/gutjnl-2012-302779)

  17. Mortality (number of participants)

    Time frame: From date of randomization until 30 days after randomization

    Death

  18. Hospital stay

    Time frame: From date of randomization until 30 days after randomization

    Days from recruitment to discharge from index admission

  19. C-reactive protein

    Time frame: At 48 hours from randomization

    C-reactive protein blood levels

  20. Number of participants with hypovolemia

    Time frame: At 24 and 48 hours from randomization

    WATERFALL trial criteria for hypovolemia (see https://www.nejm.org/doi/10.1056/NEJMoa2202884)

  21. Number of participants with fluid overload

    Time frame: From randomization to 72 h thereafter

    WATERFALL trial criteria for fluid overload (see https://www.nejm.org/doi/10.1056/NEJMoa2202884)

  22. Number of participants with acute kidney injury

    Time frame: At 24 and 48 hours from randomization

    KDIGO criteria: increase in serum creatinine of ≥0.3 mg/dL within 48 hr or ≥50% within 7 days or urine output of <0.5 mL/kg/hr for >6 hr (https://doi.org/10.1159/000339789)

  23. Number of participants with hyperkalemia

    Time frame: At 24 and 48 hours from randomization

    Venous potassium>5mEq/L

  24. Number of participants with hypercalcemia

    Time frame: At 24 and 48 hours from randomization

    Venous calcium corrected by proteins>10.5mg/dL or 2.62 mmol/L

  25. Number of participants with hyperchloremia

    Time frame: At 24 and 48 hours from randomization

    Venous chloride>106mEq/L

  26. Number of participants with acidosis

    Time frame: At 24 and 48 hours from randomization

    Venous blood pH <7.35

  27. Number of participants with hyperchloremic acidosis

    Time frame: At 24 and 48 hours from randomization

    Patients with venous chloride>106mEq/L and venous blood pH <7.35

  28. Number of participants with composite safety outcome (primary safety outcome)

    Time frame: At 24 and 48 hours from randomization

    Fluid overload or acute kidney injury or hyperkalemia or hypercalcemia or hyperchloremia or acidosis

Sponsors and collaborators

Lead sponsor

Enrique de-Madaria

Other

Collaborators

  • Asian Institute Of Medical Sciences
  • Attikon Hospital
  • Bucharest Emergency Hospital
  • Corporacion Parc Tauli
  • Emergency County Hospital Pius Brinzeu; Timisoara, Romania
  • Hayatabad Medical Complex
  • Hospital Clinico Universitario de Santiago
  • Hospital Clínico Universitario Lozano Blesa
  • Hospital Clínico Universitario de Valencia
  • Hospital Clínico Universitario de Valladolid
  • Hospital Costa del Sol
  • Hospital Dr. Jaime Mendoza Sucre Bolivia
  • Hospital General Universitario Gregorio Marañon
  • Hospital Miguel Servet
  • Hospital Nacional Rosales
  • Hospital Privado de Cordoba, Argentina
  • Hospital Regional de Alta Especialidad del Bajio
  • Hospital Universitario Central de Asturias
  • Hospital Universitario Insular Gran Canaria
  • Hospital Universitario La Fe
  • Hospital Universitario Lucus Augusti
  • Hospital Universitario Marqués de Valdecilla
  • Hospital Universitario Puerta del Mar
  • Hospital Universitario Ramon y Cajal
  • Hospital Universitario de Burgos
  • Hospital Universitario de Gran Canaria Doctor Negrín
  • Hospital del Mar
  • Hospital of Navarra
  • Hospitales Universitarios Virgen del Rocío
  • Instituto de Investigación Sanitaria Hospital Universitario de la Princesa
  • Instituto de Salud Carlos III
  • Jinling Hospital, China
  • Kalinga Hospital, Bhubaneswar
  • King Hamad University Hospital, Bahrain
  • Nuevo Hospital Iturraspe Santa Fe Argentina
  • Ohio State University
  • Postgraduate Institute of Medical Education and Research in Chandigarh
  • Prince of Wales Hospital, Shatin, Hong Kong
  • RML Specialty Hospital
  • SIDS Hospital & Research Centre Gujarat India
  • Sanatorio Allende
  • The First Affiliated Hospital of Henan University of Science and Technology
  • Universidad Miguel Hernandez de Elche
  • University Hospital Bratislava
  • University Hospital Olomouc
  • University Hospital Sestre Milosrdnice
  • University Hospital Virgen de las Nieves
  • University Hospital of Girona Dr. Josep Trueta
  • University of Utah
  • Wannan Medical College Yijishan Hospital
  • Zagazig University
  • Zhengzhou University

Registry information

Official study title

Normal Saline Versus Lactated Ringer's Solution for Acute Pancreatitis Resuscitation, an Open-label Multicenter Randomized Controlled Trial: the WATERLAND Trial

Acronym: WATERLAND

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Mar 23, 2023
Registry last updated
Jan 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.